The management of mid-stage degenerative disc disease presenting with
pain remains contentious, attributed in part to the scarcity of conclusive clinical trials.
Allogeneic mesenchymal stem cells (MSCs), procured from donors, emerge as a viable
alternative to autologous stem cell therapy. These MSCs are characterized by their
accessibility and the streamlined administration process suitable for procedure-room
settings, particularly for addressing discogenic lumbar pain. Within this manuscript, the
authors delineate their proprietary protocol involving allogeneic MSC application,
detailing the efficacy, safety, and clinical implications post-infusion into symptomatic
lumbar intervertebral discs. Their clinical series encompassed 32 subjects, 14 females
and 18 males, averaging 47.6 years of age, with a mean follow-up duration of 26.88
months. Two-year post-treatment evaluations revealed notable decrements in both ODI
and VAS scores for lumbar pain. Evaluating Macnab outcomes, 11 participants
(33.3%) showcased excellent results, 19 (57.6%) reported good outcomes, and a mere 3
(9.1%) indicated fair results. Notably, none necessitated supplementary interventions at the MSC-treated disc level. Despite the study's constraints, such as its observational
nature, potential selection and hindsight biases, and modest participant count, the
authors' findings substantiate the potential of intradiscal allogeneic MSC injections in
managing mid-stage painful degenerative disc afflictions. To fortify these preliminary
insights, future research endeavors should encompass a more regimented structure,
potentially incorporating a placebo cohort or a natural progression study group.
Keywords: Allogeneic, Mesenchymal stem cells, Low back pain, Degenerative intervertebral disc disease.
